Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Predicting Pancreatic Cancer Resectability and Outcomes Based on an Objective Quantitative Scoring System.

Toesca DAS, Jeffrey RB, von Eyben R, Pollom EL, Poullos PD, Poultsides GA, Fisher GA Jr, Visser BC, Koong AC, Chang DT.

Pancreas. 2019 May/Jun;48(5):622-628. doi: 10.1097/MPA.0000000000001314.

2.

Diagnosis of Systemic Capillary Leak Syndrome in a Young Child Treated with Intravenous Immunoglobulin in the Acute Phase.

Asmundsson ASE, Bjorklund AR, Fisher GA.

J Pediatr Intensive Care. 2018 Jun;7(2):94-96. doi: 10.1055/s-0037-1607342. Epub 2017 Oct 23.

3.

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.

Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer JP, Majeti R, Weissman IL, Takimoto CH, Supan D, Wakelee HA, Aoki R, Pegram MD, Padda SK.

J Clin Oncol. 2019 Apr 20;37(12):946-953. doi: 10.1200/JCO.18.02018. Epub 2019 Feb 27.

PMID:
30811285
4.

Detection of visually occult metastatic lymph nodes using molecularly targeted fluorescent imaging during surgical resection of pancreatic cancer.

Tummers WS, Miller SE, Teraphongphom NT, van den Berg NS, Hasan A, Longacre TA, Fisher GA, Bonsing BA, Vahrmeijer AL, Gambhir SS, Swijnenburg RJ, Rosenthal EL, Poultsides GA.

HPB (Oxford). 2019 Jul;21(7):883-890. doi: 10.1016/j.hpb.2018.11.008. Epub 2019 Feb 2.

PMID:
30723062
5.

Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.

Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA Jr, Vinik AI; CLARINET Study Investigators.

Oncologist. 2019 Apr;24(4):463-474. doi: 10.1634/theoncologist.2018-0217. Epub 2018 Oct 24.

PMID:
30355775
6.

BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.

Mirakhur B, Pavel ME, Pommier RF, Fisher GA, Phan AT, Massien C, Liyanage N, Lowenthal SP, Vinik AI.

Endocr Pract. 2018 Aug 7. doi: 10.4158/EP-2018-0296. [Epub ahead of print]

PMID:
30084687
7.

Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study.

Kardosh A, Lichtensztajn DY, Gubens MA, Kunz PL, Fisher GA, Clarke CA.

Pancreas. 2018 Sep;47(8):958-966. doi: 10.1097/MPA.0000000000001133.

8.

Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging.

Tummers WS, Miller SE, Teraphongphom NT, Gomez A, Steinberg I, Huland DM, Hong S, Kothapalli SR, Hasan A, Ertsey R, Bonsing BA, Vahrmeijer AL, Swijnenburg RJ, Longacre TA, Fisher GA, Gambhir SS, Poultsides GA, Rosenthal EL.

Ann Surg Oncol. 2018 Jul;25(7):1880-1888. doi: 10.1245/s10434-018-6453-2. Epub 2018 Apr 17.

9.

LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.

Fisher GA Jr, Wolin EM, Liyanage N, Lowenthal SP, Mirakhur B, Pommier RF, Shaheen M, Vinik AI; ELECT Study Investigators.

Endocr Pract. 2018 Mar;24(3):243-255. doi: 10.4158/EP172000.OR.

PMID:
29547049
10.

Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.

Fisher GA Jr, Wolin EM, Liyanage N, Pitman Lowenthal S, Mirakhur B, Pommier RF, Shaheen M, Vinik A; ELECT Study Group.

Oncologist. 2018 Jan;23(1):16-24. doi: 10.1634/theoncologist.2017-0284. Epub 2017 Oct 16.

11.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr.

Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.

12.

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.

Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA.

J Immunother Cancer. 2017 Mar 21;5:22. doi: 10.1186/s40425-017-0222-9. eCollection 2017.

13.

Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.

Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK.

Pancreas. 2016 Nov;45(10):1394-1400.

PMID:
27171514
14.

Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer.

Rao AD, Sugar EA, Chang DT, Goodman KA, Hacker-Prietz A, Rosati LM, Columbo L, O'Reilly E, Fisher GA, Zheng L, Pai JS, Griffith ME, Laheru DA, Iacobuzio-Donahue CA, Wolfgang CL, Koong A, Herman JM.

Pract Radiat Oncol. 2016 Nov - Dec;6(6):417-424. doi: 10.1016/j.prro.2016.05.005. Epub 2016 May 25.

15.

Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis.

Cloyd JM, Kopecky KE, Norton JA, Kunz PL, Fisher GA, Visser BC, Dua MM, Park WG, Poultsides GA.

Surgery. 2016 Sep;160(3):708-13. doi: 10.1016/j.surg.2016.04.005. Epub 2016 May 20.

PMID:
27216830
16.

EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.

Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA; ELECT Study Group *.

Endocr Pract. 2016 Sep;22(9):1068-80. doi: 10.4158/EP151172.OR. Epub 2016 May 23.

PMID:
27214300
17.

Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness Method.

Goodman KA, Patton CE, Fisher GA, Hoffe SE, Haddock MG, Parikh PJ, Kim J, Baxter NN, Czito BG, Hong TS, Herman JM, Crane CH, Hoffman KE.

Pract Radiat Oncol. 2016 May-Jun;6(3):166-175. doi: 10.1016/j.prro.2015.11.014. Epub 2015 Nov 24.

PMID:
26922700
18.

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.

Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N, Wilcox-Fogel N, Forgó E, Rajendran PS, Miranda SP, Hisamori S, Hutchison J, Kalisky T, Qian D, Wolmark N, Fisher GA, van de Rijn M, Clarke MF.

N Engl J Med. 2016 Jan 21;374(3):211-22. doi: 10.1056/NEJMoa1506597.

19.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr.

N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.

20.

Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.

Strosberg JR, Fisher GA, Benson AB, Anthony LB, Arslan B, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples WJ, Philip PA, Wolin EM, Cherepanov D, Broder MS.

World J Gastroenterol. 2015 Feb 28;21(8):2450-9. doi: 10.3748/wjg.v21.i8.2450. Review.

21.

Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity.

Pollom EL, Alagappan M, von Eyben R, Kunz PL, Fisher GA, Ford JA, Poultsides GA, Visser BC, Norton JA, Kamaya A, Cox VL, Columbo LA, Koong AC, Chang DT.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):918-25. doi: 10.1016/j.ijrobp.2014.06.066. Epub 2014 Oct 18.

PMID:
25585785
22.

Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.

Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, Iacobuzio-Donahue CA, Griffith ME, Pawlik TM, Pai JS, O'Reilly E, Fisher GA, Wild AT, Rosati LM, Zheng L, Wolfgang CL, Laheru DA, Columbo LA, Sugar EA, Koong AC.

Cancer. 2015 Apr 1;121(7):1128-37. doi: 10.1002/cncr.29161. Epub 2014 Dec 23.

23.

Limitations of body surface area-based activity calculation for radioembolization of hepatic metastases in colorectal cancer.

Lam MG, Louie JD, Abdelmaksoud MH, Fisher GA, Cho-Phan CD, Sze DY.

J Vasc Interv Radiol. 2014 Jul;25(7):1085-93. doi: 10.1016/j.jvir.2013.11.018. Epub 2014 Jan 21.

PMID:
24457263
24.

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.

Ganjoo KN, Villalobos VM, Kamaya A, Fisher GA, Butrynski JE, Morgan JA, Wagner AJ, D'Adamo D, McMillan A, Demetri GD, George S.

Ann Oncol. 2014 Jan;25(1):236-40. doi: 10.1093/annonc/mdt484.

25.

Reassessment of the current American Joint Committee on Cancer staging system for pancreatic neuroendocrine tumors.

Qadan M, Ma Y, Visser BC, Kunz PL, Fisher GA, Norton JA, Poultsides GA.

J Am Coll Surg. 2014 Feb;218(2):188-95. doi: 10.1016/j.jamcollsurg.2013.11.001. Epub 2013 Nov 6.

PMID:
24321190
26.

Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA.

Diaz LA Jr, Sausen M, Fisher GA, Velculescu VE.

Oncotarget. 2013 Oct;4(10):1856-7. No abstract available.

27.

Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.

Garrett CR, Bekaii-Saab TS, Ryan T, Fisher GA, Clive S, Kavan P, Shacham-Shmueli E, Buchbinder A, Goldberg RM.

Cancer. 2013 Dec 15;119(24):4223-30. doi: 10.1002/cncr.28358. Epub 2013 Sep 16.

28.

Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness.

Worhunsky DJ, Krampitz GW, Poullos PD, Visser BC, Kunz PL, Fisher GA, Norton JA, Poultsides GA.

HPB (Oxford). 2014 Apr;16(4):304-11. doi: 10.1111/hpb.12139. Epub 2013 Aug 29.

29.

Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process.

Strosberg JR, Fisher GA, Benson AB, Malin JL; GEPNET Treatment Consensus Panel, Cherepanov D, Broder MS, Anthony LB, Arslan B, Fisher GA, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples W, Philip PA, Strosberg J, Wolin EM.

Pancreas. 2013 Apr;42(3):397-404. doi: 10.1097/MPA.0b013e31826d3a17.

PMID:
23211372
30.

Seventh edition (2010) of the AJCC/UICC staging system for gastric adenocarcinoma: is there room for improvement?

Patel MI, Rhoads KF, Ma Y, Ford JM, Visser BC, Kunz PL, Fisher GA, Chang DT, Koong A, Norton JA, Poultsides GA.

Ann Surg Oncol. 2013 May;20(5):1631-8. doi: 10.1245/s10434-012-2724-5. Epub 2012 Nov 13.

PMID:
23149854
31.

Long-term survivors of gastric cancer: a California population-based study.

Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA.

J Clin Oncol. 2012 Oct 1;30(28):3507-15. Epub 2012 Sep 4.

PMID:
22949151
32.

Capecitabine-induced chest pain relieved by diltiazem.

Ambrosy AP, Kunz PL, Fisher GA, Witteles RM.

Am J Cardiol. 2012 Dec 1;110(11):1623-6. doi: 10.1016/j.amjcard.2012.07.026. Epub 2012 Aug 31.

PMID:
22939579
33.

Homicide as a medical outcome: racial disparity in deaths from assault in US Level I and II trauma centers.

Harris AR, Fisher GA, Thomas SH.

J Trauma Acute Care Surg. 2012 Mar;72(3):773-82. doi: 10.1097/TA.0b013e318226eb39.

PMID:
22491569
34.

Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.

Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, Arber DA, Pai RK.

Mod Pathol. 2012 Aug;25(8):1128-39. doi: 10.1038/modpathol.2012.61. Epub 2012 Apr 6.

35.

Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis.

Poultsides GA, Huang LC, Chen Y, Visser BC, Pai RK, Jeffrey RB, Park WG, Chen AM, Kunz PL, Fisher GA, Norton JA.

Ann Surg Oncol. 2012 Jul;19(7):2295-303. doi: 10.1245/s10434-012-2305-7. Epub 2012 Mar 7.

PMID:
22396008
36.

Intensity-modulated radiotherapy for pancreatic adenocarcinoma.

Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, Kunz P, Norton JA, Visser BC, Poultsides GA, Koong AC, Chang DT.

Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):e595-601. doi: 10.1016/j.ijrobp.2011.09.035. Epub 2011 Dec 22.

PMID:
22197234
37.

A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors.

Padda SK, Krupitskaya Y, Chhatwani L, Fisher GA, Colevas AD, San Pedro-Salcedo M, Decker R, Latz JE, Wakelee HA.

Cancer Chemother Pharmacol. 2012 Apr;69(4):1013-20. doi: 10.1007/s00280-011-1792-8. Epub 2011 Dec 11.

38.

Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection.

Norton JA, Harris EJ, Chen Y, Visser BC, Poultsides GA, Kunz PC, Fisher GA, Jensen RT.

Arch Surg. 2011 Jun;146(6):724-32. doi: 10.1001/archsurg.2011.129.

39.

HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.

Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK.

Appl Immunohistochem Mol Morphol. 2012 Jan;20(1):13-24. doi: 10.1097/PAI.0b013e31821c821c.

40.

Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer.

Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM, Fisher GA, Kunz PL, Van Dam J, Quon A, Desser TS, Norton J, Hsu A, Maxim PG, Xing L, Goodman KA, Chang DT, Koong AC.

Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):181-8. doi: 10.1016/j.ijrobp.2010.05.006. Epub 2011 May 5.

PMID:
21549517
41.

18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases.

Zissen MH, Kunz P, Subbarayan M, Chin FT, Conti PS, Fisher GA, Quon A.

Nucl Med Commun. 2011 May;32(5):343-7. doi: 10.1097/MNM.0b013e328344894b.

PMID:
21412178
42.

A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.

Cabebe EC, Fisher GA, Sikic BI.

Invest New Drugs. 2012 Jun;30(3):1082-7. doi: 10.1007/s10637-011-9656-y. Epub 2011 Mar 15.

PMID:
21404105
43.

Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal.

Bazan JG, Hara W, Hsu A, Kunz PA, Ford J, Fisher GA, Welton ML, Shelton A, Kapp DS, Koong AC, Goodman KA, Chang DT.

Cancer. 2011 Aug 1;117(15):3342-51. doi: 10.1002/cncr.25901. Epub 2011 Feb 1.

44.

Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma.

Chang DT, Chapman CH, Norton JA, Visser B, Fisher GA, Kunz P, Ford JM, Koong AC, Pai RK.

Cancer. 2010 Nov 15;116(22):5179-87. doi: 10.1002/cncr.25481.

45.

Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer.

Minn AY, Hsu A, La T, Kunz P, Fisher GA, Ford JM, Norton JA, Visser B, Goodman KA, Koong AC, Chang DT.

Cancer. 2010 Aug 15;116(16):3943-52. doi: 10.1002/cncr.25246.

46.

Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.

Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, Gibbs IC, Fisher GA, Koong AC.

Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):486-93. doi: 10.1016/j.ijrobp.2009.08.020. Epub 2010 Mar 28.

PMID:
20350791
47.

Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.

Galatin PS, Advani RH, Fisher GA, Francisco B, Julian T, Losa R, Sierra MI, Sikic BI.

Invest New Drugs. 2011 Oct;29(5):971-7. doi: 10.1007/s10637-010-9416-4. Epub 2010 Mar 28.

PMID:
20349264
48.

18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy.

Schellenberg D, Quon A, Minn AY, Graves EE, Kunz P, Ford JM, Fisher GA, Goodman KA, Koong AC, Chang DT.

Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1420-5. doi: 10.1016/j.ijrobp.2009.06.049. Epub 2010 Jan 7.

PMID:
20056345
49.

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.

Kunz PL, Fisher GA.

Clin Exp Gastroenterol. 2010;3:79-86. Epub 2010 Jun 28.

50.

Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis.

Chang ST, Zahn JM, Horecka J, Kunz PL, Ford JM, Fisher GA, Le QT, Chang DT, Ji H, Koong AC.

J Transl Med. 2009 Dec 11;7:105. doi: 10.1186/1479-5876-7-105.

Supplemental Content

Loading ...
Support Center